Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: Experience in Japan

Infection

Volumn 40, Issue 6, 2012, Pages 661-667

  Saito, T ^a   Fujiuchi, S ^b   Tao, Y ^c   Sasaki, Y ^d   Ogawa, K ^e   Suzuki, K ^f   Tada, A ^g   Kuba, M ^h   Kato, T ⁱ   Kawabata, M ^j   Kurashima, A ^k   Sakatani, M ^f  

^a National Hospital Organization Ibaraki Higashi National Hospital The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^b Dohoku National Hospital   (Japan)

^c FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^d SAKURA NATIONAL HOSPITAL   (Japan)

^e Meito ku   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^g Department of Internal Medicine   (Japan)

^h National Hospital Organization Okinawa National Hospital   (Japan)

ⁱ NAGARA MEDICAL CENTER   (Japan)

^j Minami Kyusyu National Hospital   (Japan)

^k TOKYO NATIONAL HOSPITAL   (Japan)

more..

Author keywords

Chronic pulmonary aspergillosis; Voriconazole

Indexed keywords

VORICONAZOLE;

AGED; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; BRONCHUS CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LIVER FUNCTION TEST; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PROSPECTIVE STUDY; SEROLOGY; SIDE EFFECT; VISUAL DISORDER;

AGED; ANTIFUNGAL AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84874109795     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0322-x     Document Type: Article

References (19)

1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.
2. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289-97.
3. Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT. "Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology. 1981;140:313-21.
4. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore). 1982;61:109-24.
5. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003;37:S265-80.
6. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011;37:865-72.
7. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.
8. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56:10-6.
9. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402.
10. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, Dauriat G, Mangiapan G, Rabbat A, Cadranel J. Treatment of chronic pulmonary aspergillosis by voriconazole in non-immunocompromised patients. Chest. 2007;131:1435-41.
11. Kohno S, Izumikawa K, Kakeya H, Miyazaki Y, Ogawa K, Amitani R, Niki Y, Kurashima A. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol. 2011;49: 688-93.
12. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, Kakeya H, Niki Y, Miyazaki Y; Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61:410-8.
13. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM (2008) Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev (4):CD007394.
14. Kitasato Y, Tao Y, Hoshino T, Tachibana K, Inoshima N, Yoshida M, Takata S, Okabayashi K, Kawasaki M, Iwanaga T, Aizawa H. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology. 2009;14:701-8.
15. Loeuille GA, Berthou C, Hilmarsdottir I, et al. Aspergillosis treated with itraconazole: analysis of 64 cases and review of literature. J Mycol Med. 1993;3:1-13.
16. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23:607-14.
17. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2003;47:3085-8.
18. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006;52:e133-7.
19. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119:527.e17-24.